Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Jong, P. Graaf, H. Brisse, P. Galluzzi, S. Göricke, A. Moll, F. Munier, M. Popovic, A. Moulin, S. Binaghi, J. Castelijns, P. Maeder (2015)
The potential of 3T high-resolution magnetic resonance imaging for diagnosis, staging, and follow-up of retinoblastoma.Survey of ophthalmology, 60 4
Nathália Grigorovski, E. Lucena, C. Mattosinho, A. Parareda, S. Ferman, J. Català, G. Chantada (2014)
Use of intra-arterial chemotherapy for retinoblastoma: results of a survey.International journal of ophthalmology, 7 4
Nicolas Yannuzzi, J. Francis, B. Marr, I. Belinsky, I. Dunkel, Y. Gobin, D. Abramson (2015)
Enucleation vs Ophthalmic Artery Chemosurgery for Advanced Intraocular Retinoblastoma: A Retrospective Analysis.JAMA ophthalmology, 133 9
M. Jong, P. Graaf, D. Noij, S. Göricke, P. Maeder, P. Galluzzi, H. Brisse, A. Moll, J. Castelijns (2014)
Diagnostic performance of magnetic resonance imaging and computed tomography for advanced retinoblastoma: a systematic review and meta-analysis.Ophthalmology, 121 5
C. Shields, Fairooz Manjandavida, S. Lally, Giulia Pieretti, Sruthi Arepalli, Emi Caywood, P. Jabbour, J. Shields (2014)
Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma.Ophthalmology, 121 7
Shigenobu Suzuki, T. Yamane, M. Mohri, A. Kaneko (2011)
Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis.Ophthalmology, 118 10
Letters Funding/Support: Dr Klufas is supported for vitreoretinal surgery fellowship Eleven patients (17.5%) in the enucleation group had a training as a John and Theiline McCone Fellow at Stein Eye Institute, University higher-risk feature (postlaminar optic nerve invasion), but not of California, Los Angeles. all received adjuvant intravenous chemotherapy (9.5%). On the Role of the Funder/Sponsor: The funder had no role in the design and conduct other hand, some patients in the OAC group also received of the study; collection, management, analysis, and interpretation of the data; intravenous chemotherapy (6.5%) or radiotherapy (1.3%). preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Heterogeneity regarding systemic treatment between both 1. Kronenburg A, Braun KP, van der Zwan A, Klijn CJ. Recent advances in treatment groups might be an important confounder. moyamoya disease: pathophysiology and treatment. Curr Neurol Neurosci Rep. Nowadays, many centers perform pre-enucleation magnetic 2014;14(1):423. resonance imaging, which in our opinion greatly adds to pre- 2. Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J treatment stage prediction of the affected eye(s) and justifies Med. 2009;360(12):1226-1237. a safe, conservative treatment approach in which no histopatho- 3. Williams M, Adas A,
JAMA Ophthalmology – American Medical Association
Published: Jan 1, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.